Will My Application Be Withdrawn if I Don’t Use the Common Forms?

March 9, 2026

NIH has extended the leniency period for using the new Biographical Sketch and Current and Pending (Other) Support (CPOS) Common Forms through May 2026, as reported in NOT-OD-26-033.  

During this leniency period: 

  • You may submit applications using the existing NIH Biosketch and Other Support format pages without penalty.
  • Submission systems will generate warnings—not errors—when Common Forms aren’t used. 

This extension is designed to give you and your institution more time to adjust as SciENcv continues system updates and agencies refine supporting guidance. While you aren’t required to switch immediately, beginning the transition now to the Common Forms will help ensure you’re fully prepared once the leniency period ends. 

Additional Resources 

Editor’s Note: On April 21, 2026, NIH released Guide Notice NOT-OD-26-079, indicating that the leniency period previously communicated in NOT-OD-26-033 will end on May 7, 2026.

Categories: You Ask, We Answer

Related News

An Update on How NIH Protects NIH-Funded Research from Undue Foreign Interference

NIH has advanced initiatives to strengthen transparency and ensure disclosure of other support. These actions build on prior work to address risks associated with foreign interference while reinforcing that honesty, transparency, and funding‑overlap prevention remain non‑negotiable requirements.

Top Stories

Embedding Replication and Reproducibility Throughout NIH Research: Key Reminders for Applications, Awards, and a New Highlighted Topic

The reliability of biomedical research is foundational to public trust in science and to ensuring that findings can benefit patients and communities. NIH’s Gold Standard Science plan advances this commitment by encouraging a culture that values replication and reproducibility. In support of this plan, NIH has launched a new Replication and Reproducibility Initiative to drive, incentivize and institutionalize replication and reproducibility efforts across the biomedical research enterprise.

Top Stories
For technical issues E-mail OER Webmaster